Allogene Therapeutics, Inc.
Latigo Biotherapeutics and Eikon Therapeutics appointed new executives following their IPOs. Allogene Therapeutics and LB Pharma also announced leadership changes, reflecting broader biotech sector restructuring. These moves are part of organizational development in the public market.
Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial o
Allogene (ALLO) reported a Q2 2026 net loss of $42.7M, or $0.13 per share, with $4.6M in collaboration revenue. Cash reserves totaled $423.6M, providing a runway into 2029. Key clinical updates include 58.3% MRD negativity in the ALPHA3 trial and a 31% ORR for ALLO-316. The company aims to expand access to CAR T therapies in community settings. FDA granted RMAT and Fast Track designations for cema-cel. Management highlighted upcoming milestones and risks, including small data sets and safety cha
Over the past 7 days, alphai's AI scored 2 news stories mentioning ALLO (Allogene Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ALLO coverage spans financial news, earnings and corporate actions.
In the last 30 days, ALLO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($63K). The most active reporter was Douglas Earl Martin, SVP, General Counsel, with 1 filing.
Management turnover may create short‑term uncertainty.
Executive departure may affect financial oversight and investor confidence.
The earnings release shows sizable cash reserves but ongoing losses, indicating near‑term financing stability but reliance on upcoming trial data.
Beat on narrower loss plus higher liquidity and ongoing ALPHA3 progress should support near-term sentiment, but it is not a fundamental re-rate without new efficacy readout.
The filing combines cash/runway updates with a clinically and regulatorily meaningful catalyst (RMAT/Fast Track) plus early MRD readouts and site-enrollment acceleration.
alphai scores every news story that mentions ALLO with an AI model for sentiment and relevance, and aggregates insider trades from Allogene Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Latigo Biotherapeutics and Eikon Therapeutics appointed new executives following their IPOs. Allogene Therapeutics and LB Pharma also announced leadership changes, reflecting broader biotech sector restructuring. These moves are part of organizational development in the public market.
2 min readAllogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial o
1 min readAllogene (ALLO) reported a Q2 2026 net loss of $42.7M, or $0.13 per share, with $4.6M in collaboration revenue. Cash reserves totaled $423.6M, providing a runway into 2029. Key clinical updates include 58.3% MRD negativity in the ALPHA3 trial and a 31% ORR for ALLO-316. The company aims to expand access to CAR T therapies in community settings. FDA granted RMAT and Fast Track designations for cema-cel. Management highlighted upcoming milestones and risks, including small data sets and safety cha
2 min readAllogene Therapeutics (ALLO) reported Q2 2026 EPS loss of 13 cents, narrower than the Zacks Consensus loss of 16 cents, helped by lower R&D costs. Collaboration revenue from related parties was $4.6 million. Cash, cash equivalents and investments rose to $423.6 million after a $200.4 million April offering. The company reiterated 2026 operating expense guidance and expects ALPHA3 interim EFS data in mid-2027.
6 min readAllogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ◦ Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatien
6 min readDelveInsight forecasts the CAR T-cell therapy market for non-Hodgkin lymphoma will grow at about 7% CAGR through 2036, driven by rising relapsed/refractory incidence and broader clinical adoption. It cites pipeline and trial activity for products including Miltenyi’s Zamtocabtagene, Novartis’ Rapcabtagene, Allogene’s Cemacabtagene, and others. Recent updates include FDA approvals for TECARTUS and label changes for YESCARTA, plus early LB2501 results from Legend Biotech.
7 min readAllogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. allo-20260618 0001737287 FALSE 0001737287 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM 8-K ____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of
4 min readAllogene Therapeutics (ALLO) stock slumped by 16.01% after announcing a $175M underwritten public offering of 87.5 million shares at $2.00 per share, significantly diluting existing shareholders. The offering, designed to fund clinical trials and R&D for its CAR-T pipeline, led to an 18% intraday price drop on increased volume. Traders are closely monitoring ALLO due to the dilution, insider selling intentions, and its high-burn, high-volatility biotech profile.
4 min readAllogene Therapeutics, Inc. announced it will host a conference call and webcast on Monday, April 13, 2026, to review interim futility analysis data from its pivotal Phase 2 ALPHA3 trial. This trial evaluates cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL). The company, a clinical-stage biotechnology firm, specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.
4 min read
